Last reviewed · How we verify
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF. Treatment will be provided as a single dose Mass Drug Administration (MDA) to the whole community. Communities will be randomised to receive either treatment with IDA and Azithromycin on the same day or separately. Active monitoring for adverse events will be conducted and the frequency of adverse events compared between individuals receiving combined MDA or separate MDA.
Details
| Lead sponsor | Lihir Medical Centre |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 20000 |
| Start date | Mon Oct 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Trachoma
- Yaws
- Lymphatic Filariases
- Scabies
- Strongyloidiasis
Interventions
- Albendazole on Day 1
- Ivermectin on Day 1
- Diethylcarbamazine on day 1
- Azithromycin on Day 1
- Azithromycin on Day 8
Countries
Papua New Guinea